BioSpace News Archive

Galapagos NV announced that primary and secondary endpoint results from the phase 3 SELECTIONinduction and maintenance study were published in The Lancet00666-8).The study, sponsored by Gilead Sciences, Inc., was designed to assess the efficacy and safety of the once-daily, oral preferential JAK1 inhibitor, filgotinib, under investigation in patients with moderately to severely active ulcerative colitis.

Alligator Bioscience presents novel supportive data from the ongoing Phase I clinical trial with the 4-1BB drug candidate ATOR-1017 developed as tumor-directed therapy for metastatic cancer.

Getinge has launched a new framework for social financing and a new social bond of SEK 570 million. The capital will be used to expand the production capacity of products that save lives.

Pharmaceutical companies are spirited about packaging advancements. The spiralling fervor is evident probably more with ophthalmic drug product manufacturers than in any other type.

Liver plays a key role in undertaking a number of critical body functions including the production of bile for digestion of food, synthesis of blood clotting compounds, detoxification, and the storage of essential sugars in the form of glycogen.

According to the report, the global fluorine-18 market was valued over US$ 1.5 Bn in 2020 and is projected to expand at a CAGR of 7.5% from 2021 to 2031.

The worldwide pharmaceutical industry is experiencing notable growth in research and development activities.

Pharvaris announced that Anne Lesage, Ph.D., chief early development officer at Pharvaris, will present bradykinin challenge data supporting the pharmacokinetic and pharmacodynamic profile of PHA121 for the treatment of hereditary angioedema, at the 12th C1 Inhibitor Deficiency and Angioedema Workshop, to be held virtually June 3-6, 2021.

According to the report, the global NICU catheters market was valued at US$ 400 Mn in 2020 and is projected to expand at a CAGR of 4.5% from 2021 to 2031.

According to the report, the global interventional pulmonology market was valued over US$ 3 Bn in 2020 and is projected to expand at a CAGR of ~9% from 2021 to 2031.